PUBLIC COMPANY
save$ACADACADIA PHARMACEUTICALS INC
$ACAD29.04-3.87%San Diego, CA, USupdated 4h ago
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
community read0 votes
pipeline
5
marketed
2
phase 3
1
catalysts ytd
5
approvals ytd
1
recalls ytd
0
Pipeline(5)
pipeline depth5 products
1Phase 32Marketed2Unknown
Upcoming
Recent(90d)
earnings (2)
Active trials
- phase3OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
- phase2ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- phase3ACP-204 in Adults With Alzheimer's Disease Psychosis
- phase3ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
- phase2Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
- phase3Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
- phase3Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
- phase3Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 7, 26SELLSchneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER−$60K↗
- Apr 7, 26SELLKihara James· PRINCIPAL ACCOUNTING OFFICER−$23K↗
- Mar 26, 26SELLSchneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER−$69K↗
- Mar 26, 26SELLKihara James· PRINCIPAL ACCOUNTING OFFICER−$24K↗
- Mar 26, 26SELLSchneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER−$804↗
- Mar 26, 26SELLKihara James· PRINCIPAL ACCOUNTING OFFICER−$261↗
- Mar 25, 26SELLOwen Adams Catherine· Chief Executive Officer−$250K↗
- Mar 25, 26SELLSchneyer Mark C.· EVP, CHIEF FINANCIAL OFFICER−$90K↗
- Mar 25, 26SELLRhodes Jennifer J· EVP, CHIEF LEGAL OFFICER, SEC−$83K↗
- Mar 25, 26SELLThompson Elizabeth H.Z.· EVP, Head of Research & Dev−$74K↗
- Mar 25, 26SELLKihara James· PRINCIPAL ACCOUNTING OFFICER−$18K↗
routine RSU / option mechanics (6)
- Apr 5, 26option exerciseKihara James · PRINCIPAL ACCOUNTING OFFICER2,010 sh
- Apr 5, 26option exerciseSchneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER5,276 sh
- Apr 5, 26option exerciseKihara James · PRINCIPAL ACCOUNTING OFFICER2,010 sh
- Apr 5, 26option exerciseSchneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER5,276 sh
- Mar 25, 26option exerciseKihara James · PRINCIPAL ACCOUNTING OFFICER2,142 sh
- Mar 25, 26option exerciseSchneyer Mark C. · EVP, CHIEF FINANCIAL OFFICER6,178 sh
🐶 Hiring Signal
next earnings Nov 4, 2026
News
- On second try, Acadia drug gets nod from European regulatorsThe influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.biopharma_dive · 1mo ago
- Celiac disease is entering a new era of therapeutic innovationFor the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.biopharma_dive · 2mo ago
- Rapport ‘fully prepared’ to launch seizure drug solo, CEO saysIn a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.biopharma_dive · 2mo ago
- Reigniting Your Curiosity During FellowshipMegan M. Dupuis, MD, PhD, discusses how oncology fellows can keep their personal and professional curiosities alive during fellowship.onclive · 3mo ago
Data sources
last refreshed 29m ago
Found something off?
comments(0)
5-min edit window · permanent after that